Sharvina Ziyeh, M.D.
Medical Oncology
Assistant Clinical Professor, Department of Medical Oncology & Therapeutics Research
Sharvina Ziyeh, M.D., first pursued a medical career to help address the needs of underrepresented patients. As a medical oncologist, she connects with patients and builds trust through a process of shared decision-making, with the goal of not only extending life but preserving quality of life.
Dr. Ziyeh earned her medical degree from Saint Louis University in Missouri, then completed an internal medicine residency and a hematology/oncology fellowship at UCLA-Olive View Medical Center. The fellowship provided unique opportunities for her to train at other medical centers, including Cedars-Sinai and Kaiser Permanente Los Angeles Medical Center, and to run her own continuity clinic.
As a clinical research coordinator at UCSF, Dr. Ziyeh was part of the team behind a multicenter phase 2 clinical trial evaluating a combination protocol of targeted treatments for chemotherapy-resistant pancreatic adenocarcinoma. As a fellow, she co-authored the review article, “Advances in Endocrine Therapy for Hormone Receptor-Positive Advanced Breast Cancer,” which appeared in Current Oncology Reports. She is a member of the American Society of Clinical Oncology, the American College of Physicians and the American Society of Hematology.
Location
South Bay
Torrance, CA 90503
Education & Experience
Board Certifications
- 2024, American Board of Internal Medicine, Oncology
- 2021, American Board of Internal Medicine
Degrees
- 2018, Doctor of Medicine, Saint Louis University School of Medicine; St Louis, Missouri
Fellowship
- 2024, Hematology/Oncology, UCLA-Olive View Medical Center, Los Angeles, California
Residency
- 2021, Hematology/Oncology, UCLA-Olive View Medical Center, Los Angeles, California
Professional Experience
- 2024-present, Assistant Clinical Professor, Department of Medical Oncology and Therapeutics Research, City of Hope, Torrance (South Bay), California
- 2012-2014, Clinical Research Coordinator, University of California, San Francisco, California
Publications
- Kim K, Ziyeh S, Kim P. Extranodal diffuse large B-cell lymphoma presenting with extensive organ involvement. BMJ Case Reports CP 2024;17:e257416
- Ziyeh S, Wong L, Basho RK. Advances in Endocrine Therapy for Hormone Receptor-Positive Advanced Breast Cancer. Curr Oncol Rep. 2023; 25(7):689- 698. doi:10.1007/s11912-023-01393-6
- Mongelluzzo J, Tu B, Grimes B, et al (Ziyeh S). Correlation of Physical Exam Findings with Fever in Patients with Skin and Soft Tissue Infections. West J Emerg Med. 2017;18(3):398-402. doi:10.5811/westjem.2016.12.32838
- Ko AH, Bekaii-Saab T, Van Ziffle J, et al (Ziyeh S). A Multicenter, Open-Label Phase II Clinical Trial of Combined MEK plus EGFR Inhibition for Chemotherapy-Refractory Advanced Pancreatic Adenocarcinoma. Clin Cancer Res. 2016; 22(1):61-68. doi:10.1158/1078-0432.CCR-15-0979
- Kelley R, Siu L, Van Loon K, Tolcher A, Razak A, Ziyeh S, Beeram M, Bedard P, Arcos R, Gao B, Trail P, Adriaens L, Brownstein A., Lowy I, Papadopoulos K. Phase 1 First-in-human (FIH) Study of Nesvacumab (REGN910) A Fully Human and Selective Angiopoietin-2 (Ang2) Monoclonal Antibody (Mab): Results from Hepatocellular Carcinoma (HCC) Cohort. Journal of Clinical Oncology. 2014; 32. 2540-2540.